Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
verfasst von:
Lei Liang, Chao Li, Ming-Da Wang, Hong Wang, Ya-Hao Zhou, Yong-Yi Zeng, Wan-Guang Zhang, Ting-Hao Chen, Nan-Ya Wang, Jie Li, Yao-Ming Zhang, Yu Wang, Wei-Min Gu, Hao Xing, Yong-Kang Diao, Wan Yee Lau, Cheng-Wu Zhang, Timothy M. Pawlik, Feng Shen, Dong-Sheng Huang, Tian Yang
Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator for individualized estimating the net survival benefit of adjuvant TACE for patients with resected HCC.
Methods
From a multicenter database, consecutive patients undergoing curative resection for HCC were enrolled and divided into the developing and validation cohorts. Using the independent survival predictors in the developing cohort, two nomogram models were constructed for patients with and without adjuvant TACE, respectively, which predictive performance was validated internally and externally by measuring concordance index (C-index) and calibration. The difference between two estimates of the prediction models was the expected survival benefit of adjuvant TACE.
Results
A total of 2514 patients met the inclusion criteria for the study. The nomogram prediction models for patients with and without adjuvant TACE were, respectively, built by incorporating the same eight independent survival predictors, including portal hypertension, Child–Pugh score, alpha-fetoprotein level, tumor size and number, macrovascular and microvascular invasion, and resection margin. These two prediction models demonstrated good calibration and discrimination, with all the C-indexes of greater than 0.75 in the developing and validation cohorts. A browser-based calculator was generated for individualized estimating the net survival benefit of adjuvant TACE.
Conclusions
Based on large-scale real-world data, an easy-to-use online calculator can be adopted as a decision aid to predict which patients with resected HCC can benefit from adjuvant TACE.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
HCC
Hepatocellular carcinoma
TACE
Transcatheter arterial chemoembolization
RCT
Randomized controlled trial
CT
Computed tomography
MRI
Magnetic resonance imaging
PS
Performance status
ECOG
Eastern cooperativse oncology group
ASA
American society of anesthesiologists
HBV
Hepatitis B virus; HCV, hepatitis C virus
ALT
Alanine aminotransferase
AST
Aspartate transaminase
AFP
Alpha-fetoprotein
C-index
Concordance index
CI
Confidence interval
HR
Hazard ratio
To the editor,
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide [1]. Surgical resection represents a common approach to treat HCC and provides the possibility of cure [2]. Long-term prognosis after HCC resection is, however, still poor due to the high incidence of recurrence [3‐5]. Transcatheter arterial chemoembolization (TACE) has been used in the postoperative setting as a means to decrease risk of recurrence and improve survival [6‐8]. Whereas, in clinical practice, controversy persists relative to the role of adjuvant TACE for resected HCC [9‐11]. The reasons for these disparate results are undoubtedly multifactorial, yet may relate to patient selection. Specifically, only certain high-risk patients with resected HCC may benefit from adjuvant TACE [12]. The objective of the current study was to construct a decision aid using a large multicenter database to predict which patient with resected HCC had a survival benefit from adjuvant TACE. In addition, we sought to estimate the magnitude of the survival benefit for given individual patients. A web-based decision tool was provided for clinicians and patients to aid in the decision-making process regarding adjuvant TACE after HCC resection. Patients and methods for this study are described in detail in Additional file 1.
Anzeige
Overall survival
All 2514 patients with HCC underwent curative liver resection were included (Additional file 2: Figure S1). Among them, 1755 and 759 patients were randomly segregated to the development and validation cohort, respectively (Table 1). Compared with patients who did not receive adjuvant TACE, patients who had adjuvant TACE had a longer survival in both the development and validation cohorts (all P < 0.001) (Additional file 3: Figure S2).
Table 1
Baseline characteristics of patients with and without adjuvant TACE in the developing and validation cohorts
Variables
The developing cohort (N = 1755)
The validation cohort (N = 759)
With adjuvant TACE (n = 533)
Without adjuvant TACE (n = 1222)
With adjuvant TACE (n = 224)
Without adjuvant TACE (n = 535)
Preoperative variables
Male sex
476 (89.3)
1080 (88.4)
198 (88.4)
468 (87.5)
Age > 65 years
89 (16.7)
260 (21.3)
29 (12.9)
115 (21.5)
Co-morbid illness
111 (20.9)
228 (18.7)
72 (32.1)
160 (29.9)
PS, 1–2/0
161/372 (30.2/69.8)
345/877 (28.2/71.8)
35/189 (15.7/84.3)
82/453 (15.3/84.7)
ASA score > 2
56 (10.5)
182 (14.9)
19 (8.5)
81 (15.1)
Etiology of liver disease, HBV/HCV/HBV + HCV/other
446/26/15/46 (83.7/4.9/2.8/8.6)
1010/73/27/112 (82.7/6.0/2.2/9.2)
193/9/4/18 (86.2/4.0/1.8/8.0)
446/32/9/48 (83.4/6.0/1.7/9.0)
Cirrhosis
391 (73.4)
958 (78.4)
157 (70.1)
421 (78.7)
Portal hypertension
115 (21.6)
329 (26.9)
37 (16.5)
129 (24.1)
Child–Pugh grade, A/B
489/44 (91.7/8.3)
1075/147 (88.0)
207/17 (92.4/7.6)
467/68 (87.3/12.7)
Preoperative ALT level > 40 U/L
277 (52.0)
683 (55.9)
111 (49.6)
289 (54.0)
Preoperative AST level > 40 U/L
284 (53.3)
703 (57.5)
141 (62.9)
314 (58.7)
Preoperative AFP level > 400 ug/L
206 (38.6)
489 (40.0)
87 (38.8)
198 (37.0)
Maximum tumor size, ≥ 10.0/5.0–9.9/< 5.0 cm
128/212/193 (24.0/39.8/36.2)
204/443/575 (16.7/36.3/47.1)
45/96/83 (20.1/42.9/37.1)
77/200/258 (14.4/37.4/48.2)
Tumor number, ≥ 3/2/1
91/82/360 (17.1/15.4/67.5)
159/121/942 (13.0/9.9/77.1)
33/35/156 (14.7/15.6/69.6)
70/50/415 (13.1/9.3/77.6)
Macrovascular invasion
67 (12.6)
104 (8.5)
35 (15.6)
50 (9.3)
Intraoperative variables
Intraoperative blood loss > 600 mL
117 (22.0)
263 (21.5)
42 (18.8)
104 (19.4)
Intraoperative blood transfusion
145 (27.2)
307 (25.1)
45 (20.1)
132 (24.7)
Operation time > 180 min
86 (16.1)
214 (17.5)
30 (13.4)
84 (15.7)
Anatomical resection
145 (27.2)
331
(27.1)
63 (28.1)
129 (24.1)
Major hepatectomy
157 (29.5)
318 (26.0)
56 (25.0)
132 (24.7)
Postoperative pathological variables
Microvascular invasion
306 (57.4)
619 (50.7)
134 (59.8)
270 (50.5)
Poor tumor differentiation
397 (74.5)
918 (75.1)
175 (78.1)
415 (77.6)
Incomplete tumor encapsulation
334 (62.7)
785 (64.2)
155 (69.2)
344 (64.3)
Resection margin < 1 cm
179 (33.6)
386 (31.6)
76 (33.9)
162 (30.3)
AFP alpha-fetoprotein, ALT alanine aminotransferase, ASA American Society of Anesthesiologists, AST aspartate transaminase, HBV hepatitis B virus, HCV hepatitis C virus, PS performance status, TACE transcatheter arterial chemoembolization
Independent predictors of survival
Univariable and multivariable Cox regression analyses of the development cohort demonstrated that independent predictors associated with overall survival after HCC resection among patients treated with and without adjuvant TACE included portal hypertension, Child–Pugh grade, preoperative AFP level, tumor size, tumor number, macrovascular invasion, microvascular invasion, and resection margin (all P < 0.05). (Additional file 4: Table S1 and Additional file 5: Table S2).
Development of the prediction models
Two different nomogram models that integrated independent factors associated with overall survival were constructed to predict outcomes among patients who did and did not receive adjuvant TACE (Fig. 1a, b). To estimate the net survival benefit from adjuvant TACE, these two nomograms were compared and the difference between the two estimates was the expected net survival benefit from the addition of adjuvant TACE.
Fig. 1
Nomograms to calculate the expected survival time, and 3- and 5-year survival probabilities for a patients who attempt to undergo adjuvant TACE and b patients who attempt not to undergo adjuvant TACE. Thus, the difference of the expected values between the two estimates is the expected net survival benefit of adjuvant TACE. Calibration plots of the models for predicting 3-year and 5-year survival for patients with and without adjuvant TACE c in the developing cohort and d in the validation cohort, respectively. e Screenshots of the web-based calculator for individualized estimates of the expected net survival benefit of adjuvant TACE for patients with resected hepatocellular carcinoma. Website: http://www.asapcalculate.top/Cal5_en.html. For example, suppose there is a male patient without portal hypertension (Child–Pugh A) who have underwent curative resection for a single HCC tumor (tumor size: 8.0 cm, without macrovascular invasion but with microvascular invasion). His preoperative AFP level was 718 ug/L (≥ 400 ug/L), and the tumor resection margin was 0.8 cm (< 1 cm). After putting these data into these specific parameters, we can get the expected net survival time benefit of adjuvant TACE was 9.0 months, and the net survival benefits of 3-year and 5-year survival rates are 11.7% and 9.3%, respectively
×
Validation of the prediction models
Bootstrapping with 400 resamples in the development cohort demonstrated good predictive performance, with the C-indexes of 0.791 (95% CI 0.742–0.840) and 0.810 (95% CI 0.779–0.841) for patients with and without adjuvant TACE, respectively. Accordingly, the C-indices were 0.756 (95% CI 0.678–0.834) and 0.765 (95% CI 0.720–0.810) in the validation cohort. There was also good calibration curve to predict 3- and 5-year survival probabilities among patients treated with and without adjuvant TACE, respectively (all P > 0.05) (Fig. 1c, d).
Anzeige
Construction of the online calculator
Based on the formula of the nomogram prediction models, an Internet browser-based software tool was constructed to predict the net survival benefit of adjuvant TACE for an individual patient, including the expected net survival time, and the increased 3- and 5-year survival probabilities (Fig. 1e). The corresponding score and the formula to calculate survival probability were provided (Additional file 6: Table S3). The online calculator is available for free use at: http://asapcalculate.top/Cal5_en.html. After the user inputs all the requested information relative to the prognostic factors, the predicted survival improvement associated with the addition of adjuvant TACE, including the expected survival time and the 3- and 5-year survival probabilities, is generated and displayed.
In summary, a survival prediction model that incorporated eight independent variables associated with survival was constructed to derive an individualized estimate of the net survival benefit of adding adjuvant TACE to a patient’s post-resection HCC treatment plan. The nomograms and online calculator had good predictive accuracy, and discrimination was validated. The calculator may help provide an estimate of the net survival benefit associated with adjuvant TACE for an individual patient following HCC resection. This tool may assist clinicians and patients in quantifying the benefit of adjuvant TACE after HCC resection and inform real-word discussions on this topic.
Declarations
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of all participating hospitals.
Informed consent
The study protocol was approved by the Institutional Review Board of all participating hospitals, and informed consent from the patients was waived. Written, informed consent for the data to be used for clinical researches was obtained from all enrolled patients.
Congress publication
The abstract of this study has been presented as an oral presentation in the Congress of “the 11th Asia-Pacific Primary Liver Cancer Expert, APPLE 2021” (August 13–15, 2021, Korea), and has been also presented as an oral presentation in the Congress of “the LIVER WEEK 2021” (May 13–15, 2021, Korea) and won a “Foreign Investigator Award”.
Competing interests
All authors declare that they have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
verfasst von
Lei Liang Chao Li Ming-Da Wang Hong Wang Ya-Hao Zhou Yong-Yi Zeng Wan-Guang Zhang Ting-Hao Chen Nan-Ya Wang Jie Li Yao-Ming Zhang Yu Wang Wei-Min Gu Hao Xing Yong-Kang Diao Wan Yee Lau Cheng-Wu Zhang Timothy M. Pawlik Feng Shen Dong-Sheng Huang Tian Yang
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.
Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.
Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
